Clinical trials: Prostate Cancers
Prostate Cancer
Biomarker Study of Neoadjuvant Vitamin E in Patients With Locally Treatable Prostate Cancer
The purpose of this study is to find out if vitamin E can help treat prostate cancer. Vitamin E acts primarily as an anti-oxidant. By decreasing the oxidation in the cancer cell, the tumor cells may die.
- Trial name
- NCT00809458
- Testing
- Vitamin E
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Cancer
Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease
This study is for patients who have a high risk of metastatic prostate cancer (cancer that has spread outside of the prostate) who are going to have radical prostatectomy.
- Trial name
- EDRN-FACBC (NCT03081884)
- Testing
- FACBC PET-CT Imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Emory University
Prostate Cancer
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer
Background: The immune system is the cells and organs in the body that recognize and fight infection and cancer. The prostate specific antigen (PSA)/TRICOM (PROSTVAC) vaccine might teach the immune system to find and kill certain…
- Trial name
- NCT02933255
- Testing
- PROSTVAC-V/F, Nivolumab, Prostatectomy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer
This is a double-blind, placebo-controlled, multiregional Phase1/2 study to characterize the pharmacokinetic and pharmacodynamic responses to orteronel when administered concomitantly with prednisone in Chemotherapy-Naive…
- Trial name
- NCT01666314
- Testing
- Orteronel, Prednisone
- Where
- United States
- Volunteers
- 137 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
The study was a three-arm, active-control, multi-centre, parallel group study.
- Trial name
- NCT00295750
- Testing
- Degarelix, Leuprolide 7.5 mg
- Where
- 35 sites in United States, Canada and 10 more
- Volunteers
- 620 people
- Sponsor
- Ferring Pharmaceuticals
Adenocarcinoma of the Prostate
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
The area around a tumor ("pre-metastatic niche") may be an area to which cancer cells are attracted. The study doctor will take blood and tumor samples to look for certain features linked with response to treatment so that they…
- Trial name
- NCT01832259
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Utah
Prostate Cancer
Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.
In summary this trial will test whether this new surgical technique can be used to make surgery safer and more effective whilst allowing improved quality of life for patients having surgery for prostate cancer.
- Trial name
- NeuroSAFEPROOF (NCT03317990)
- Testing
- NeuroSAFE procedure, Standard RARP
- Where
- 5 sites in United Kingdom
- Volunteers
- 407 people
- Sponsor
- University College, London
Prostate Cancer
Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
The goal of this clinical research study is to learn if adding dovitinib to the combination of abiraterone acetate and prednisone may help to control metastatic CRPC. The safety of this drug combination will also be studied.
- Trial name
- NCT01994590
- Testing
- Dovitinib, Abiraterone Acetate, Prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Obesity, Prostate Cancer
Effect of Weight Loss on Prostate Cancer Pathology
The purpose of this study is to determine if weight loss prior to radical prostatectomy effects chemical substances in the blood stream and prostate tissue that may affect prostate cancer development and progression.
- Trial name
- NCT00475982
- Testing
- Weight Loss, No Weight Loss Group
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with…
- Trial name
- NCT02470897
- Testing
- Radiation Therapy Treatment Planning and Simulation, SBRT
- Where
- 3 sites in United States
- Volunteers
- 115 people
- Sponsor
- University of Wisconsin, Madison
Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant
Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
This study investigates if a new drug (PSMA) makes prostate cancer easier to identify in positron-emission tomography (PET) imaging.
- Trial name
- NCT03822845
- Testing
- Ga-68 PSMA-HBED-CC PET
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Michael Graham PhD, MD
Prostatic Neoplasms
Amifostine to Protect the Rectum During External Beam Radiotherapy for Prostate Cancer
This study will evaluate the safety and effectiveness of a drug called amifostine in reducing the bowel side effects of radiation treatment for prostate cancer.
- Trial name
- NCT00040365
- Testing
- Amifostine trihydrate, Radiation therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.
- Trial name
- NCT03209492
- Testing
- Leuprorelin acetate
- Where
- Japan
- Volunteers
- 333 people
- Sponsor
- Takeda
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Recurrent Prostate Cancer
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
MMR-deficient cancers of any histologic type appear to be very sensitive to PD-1 blockade with pembrolizumab, and similar data are also beginning to emerge for nivolumab and other immune checkpoint inhibitors.
- Trial name
- NCT04019964
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate, Cancer
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Objective: To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.
- Conditions
- Prostate, Cancer, Hormonal Cycling
- Trial name
- NCT00586898
- Testing
- GnRH, Ketoconazole, Bicalutamide
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.
- Trial name
- NCT02758132
- Testing
- Denosumab, Enzalutamide, Abiraterone
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Hawaii
Prostate Cancer
Hypofractionated Stereotactic Body Radiation Therapy (SBRT)
The purpose of this study is to evaluate the safety and tolerability of using radiation therapy with 5 fractions of radiation to treat prostate cancer with guidance of radiation using the Calypso 4D Treatment System (Calypso).A…
- Trial name
- NCT01288534
- Testing
- Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Michigan Rogel Cancer Center
Obesity, Prostate Cancer
Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy
The purpose of this study is to test how a weight management program affects substances in the blood called biomarkers that can show the presence or severity of cancer, compared to a standardized diet and exercise educational…
- Trial name
- WARRIOR (NCT03261271)
- Testing
- Weight Loss Program, Standardized educational flyer, Weight Maintenance Program
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Prostatic Neoplasms
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination…
- Trial name
- AMPLITUDE (NCT04497844)
- Testing
- Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone
- Where
- 387 sites in United States, Argentina and 31 more
- Volunteers
- 696 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.